Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare, X-linked recessive genetic disease caused ...

A universal vaccine would work to help combat the development of AMR in several ways. Firstly, it would protect the individual from getting infected. Prevention of primary infection removes the ...

In a statement, Japan's Astellas said the specific terms of the settlement were confidential; however, a regulatory filing has revealed that the Indian pharma group has agreed to pay $90 million to ...

Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...

Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna ...

In understanding what makes the patient voice so essential to successful drug development, let’s take a critical eye to what is showing to be beneficial, particularly for mid-size pharmaceutical ...

The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...

Many companies have tried to jump into the GLP-1 gold rush with their own versions of the blockbuster obesity drug. Prive Bio, whose CEO Laurent Audaly met with pharmaphorum’s Jonah Comstock last ...

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO ...

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D collaboration that includes a $350 million upfront payment.

"The government has claimed that the deal will only cost around £1 billion per year, but the UK's new commitment to double ...

Wegovy is the first GLP-1 to be available in the US for weight loss in an oral formulation, and Novo Nordisk has already reported strong take-up, with 170,000 people taking the drug as of last week, ...